DCVC Announcements
First Investment: 2021
Shennon has built an ultra-high-throughput profiling engine that allows it to analyze millions of immune cells on the single-cell level, searching for rare receptors and other targets that will help the company create more effective immunotherapies for solid tumors.
News & Insights
Explore Companies
Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance
Avicenna Biosciences
Using AI to speed through the last mile of drug discovery
Latus Bio
Finding precisely tuned viral vectors for gene therapy in CNS disorders
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors